Shots:
- Innate Pharma completed enrollment in the P-I (IPH4502-101) dose-escalation study of IPH4502, its Nectin-4 exatecan ADC, enrolling 76 pts across France & the US, incl. those with UC, NSCLC, HNSCC, breast, ovarian, gastric, esophageal, & colorectal cancers
- Trial is evaluating the safety, tolerability, & preliminary antitumor activity of IPH4502 monotx. in advanced Nectin-4–expressing solid tumors. Preliminary data from 76 pts are expected by year-end & will guide dose optimization in selected tumor types
- IPH4502 features an exatecan topoisomerase I inhibitor payload, designed to potentially overcome MDR1-mediated resistance associated with MMAE-based ADCs without requiring CYP2D6 genotyping
Ref: Businesswire | Image: Innate Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
